Tumor proportion in colon cancer: results from a semiautomatic image analysis approach.
Biomarker
Colon cancer
ImageJ
Tumor stroma ratio
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
20
09
2019
accepted:
27
01
2020
revised:
13
01
2020
pubmed:
23
2
2020
medline:
30
7
2020
entrez:
21
2
2020
Statut:
ppublish
Résumé
The tumor stroma ratio (TSR) is a promising prognostic biomarker in colon cancer, which could provide additional risk stratification for therapy adaption. The objective of our study was the investigation of the prognostic significance of TSR at different tumor sites in a simple semiautomatic approach with the open-source program ImageJ. We investigated 206 pT3 and pT4 adenocarcinomas of no special type. According to our established thresholds, 31 tumors (15%) were classified as low tumor proportion (TP) (≤ 15% TP), 42 tumors (20%) were classified as high TP (≥ 54% TP), and 133 tumors (65%) were classified as medium TP. High and low TP were associated with an adverse overall survival in comparison to medium TP (p = 0.001 and p = 0.03). Furthermore, the TP was an independent risk factor of occurrence of distant metastasis next to T status, microsatellite status, and tumor budding. The 5-year survival rate was 49% in patients with high TP, 48% in patients with low TP, and 68% in patients with medium TP (p = 0.042, n = 160). Patients with a high TP had less often tumor budding (p = 0.012), lymphovascular invasion (p = 0.049), and less harvested lymph nodes (p = 0.042) in comparison to low TP tumors. The results provide first evidence that a high tumor proportion/low stroma proportion is also associated with an adverse prognosis and that this subgroup might be difficult to identify with other classical histopathologic characteristics that are linked to an adverse prognosis.
Identifiants
pubmed: 32076815
doi: 10.1007/s00428-020-02764-1
pii: 10.1007/s00428-020-02764-1
pmc: PMC7985049
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
185-193Commentaires et corrections
Type : ErratumIn
Références
Nat Biotechnol. 2011 Nov 13;29(12):1120-7
pubmed: 22081019
Histopathology. 2017 Jul;71(1):12-26
pubmed: 28165633
Ann Oncol. 2014 Mar;25(3):644-651
pubmed: 24458470
Nat Cell Biol. 2010 May;12(5):468-76
pubmed: 20418870
Virchows Arch. 2018 Oct;473(4):405-412
pubmed: 30030621
Virchows Arch. 2018 Aug;473(2):189-197
pubmed: 29626253
Br J Cancer. 2010 May 11;102(10):1519-23
pubmed: 20407439
Int J Colorectal Dis. 2018 Aug;33(8):1115-1124
pubmed: 29785462
Eur J Cancer. 2010 Mar;46(4):720-8
pubmed: 20044247
Cell Oncol. 2007;29(5):387-98
pubmed: 17726261
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Surgeon. 2017 Dec;15(6):329-335
pubmed: 28629870
Diagn Pathol. 2018 Mar 20;13(1):20
pubmed: 29558947
Breast Cancer Res Treat. 2019 Jan;173(1):55-64
pubmed: 30302588
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Gynecol Oncol. 2014 Jan;132(1):81-6
pubmed: 24219981
Cell Oncol (Dordr). 2019 Jun;42(3):331-341
pubmed: 30825182
Ann Oncol. 2013 Jan;24(1):179-85
pubmed: 22865778
Histopathology. 2018 Aug;73(2):197-206
pubmed: 29457843
Cell Oncol. 2009;31(3):169-78
pubmed: 19478385
Histopathology. 2018 Feb;72(3):391-404
pubmed: 28746977
Cell Stem Cell. 2011 May 6;8(5):511-24
pubmed: 21419747
Mod Pathol. 2017 Sep;30(9):1299-1311
pubmed: 28548122
Clin Cancer Res. 2013 Sep 15;19(18):4905-7
pubmed: 24009149
World J Gastroenterol. 2015 Nov 21;21(43):12218-33
pubmed: 26604632
JMIR Res Protoc. 2019 Jun 14;8(6):e13464
pubmed: 31199317
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593